Drug maker's PR firm is force behind blood clot awareness campaign

Moynihan, Ray
June 2008
BMJ: British Medical Journal (International Edition);6/28/2008, Vol. 336 Issue 7659, p1460
Academic Journal
The article discusses an public awareness campaign by the public relations firm Fleishman-Hilliard regarding the danger of blood clots. Drug professor Alasdair Millar has objected to the campaign's proposal that all hospital patients receive injections to reduce the chance of blood clots. The campaign was funded by the drug company Sanofi-Aventis, which offers the medication enoxaparin to prevent clots. Hospital guidelines also advocate the use of enoxaparan.


Related Articles

  • Agency duo strikes oil. Krajewski, Steve // Adweek Western Edition;9/9/96, Vol. 46 Issue 37, p58 

    Reports on the selection of GSD&M and Fleishman-Hillard to handle a public education initiative by the American Petroleum Institute and the Independent Petroleum Association of America. Other agencies considered; Reason for the selection; Background on the public education initiative.

  • Multicultural Campaign.  // PR News;10/16/2006, Vol. 62 Issue 40, p23 

    The article describes the public relations campaign launched by the New Jersey Department of Health and Senior Services to raise public awareness for its rapid HIV test, which provides results in 20 minutes, rather than days or weeks. With the help of Fleishman-Hillard, the campaign, which...

  • Fleishman-Hillard funds news council. Evans, E.S. // St. Louis Journalism Review;Feb98, Vol. 28 Issue 203, p5 

    States that a news council is being funded by Fleishman-Hillard Incorporated. Circumstances surrounding the funding; Indepth look at the semi-annual report of the council; Reference to Ann Barkelew, senior vice president of Fleishman-Hillard.

  • Sanofi: Time not right to sell off beauty unit.  // WWD: Women's Wear Daily;9/8/1997, Vol. 174 Issue 48, p4 

    Focuses on pharmaceuticals and beauty products company, Sanofi's executive vice president for administration and finance, Jean-Paul Leon's issuance of a statement to clarify French business newspapers report that the company is planning to sell off its beauty division. Overview on Sanofi's...

  • Beauty sales at Sanofi decline 2%.  // WWD: Women's Wear Daily;4/14/1995, Vol. 169 Issue 72, p9 

    Reports on the decline in sales of Sanofi SA's beauty products and fragrances during the first quarter of 1995.

  • Third alternative. Horton, Kathleen // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p92 

    Reports on Sanofi SA's acquisition of the rights to market Hyalgan (hyaluronate) in the United States.

  • THE WEEK IN LOBBYING.  // PRWeek (London);5/6/2011, p9 

    The article covers issues related to lobbying in Great Britain as of May 2011 including the closure of the Edinburgh, Scotland office of public relations (PR) firm Fleishman-Hillard, the controversy facing tobacco group British American Tobacco concerning its alleged involvement in covert...

  • Sanofi operating net drops 35% in fragrance, beauty areas in '94.  // WWD: Women's Wear Daily;3/16/1995, Vol. 169 Issue 51, p24 

    Reports on the financial performance of Sanofi in 1994. Operating profits from fragrance and beauty products; Sales; Earnings.

  • Sanofi beauty sales off 4.3% in 4th quarter.  // WWD: Women's Wear Daily;2/11/1997, Vol. 173 Issue 28, p9 

    Reports on the decline in Sanofi SA beauty sector's sales in the fourth quarter of 1996. Expected increase in earnings as compared to year-ago results; Growth in Yves Saint Laurent's Opium lines for men and women; Increase in total company sales.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics